These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30607817)

  • 21. Neratinib for the treatment of early-stage, hormone receptor-positive, HER2-overexpressed breast cancer.
    Jerez Y; Herrero B; Arregui M; Morón B; Martín M; Echavarría I
    Future Oncol; 2020 Jun; 16(17):1165-1177. PubMed ID: 32458702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neratinib in HER2-Positive Breast Cancer Patients.
    Paranjpe R; Basatneh D; Tao G; De Angelis C; Noormohammed S; Ekinci E; Abughosh S; Ghose R; Trivedi MV
    Ann Pharmacother; 2019 Jun; 53(6):612-620. PubMed ID: 30607980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New protein kinase inhibitors in breast cancer: afatinib and neratinib.
    Zhang X; Munster PN
    Expert Opin Pharmacother; 2014 Jun; 15(9):1277-88. PubMed ID: 24787047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neratinib: an option for HER2-positive metastatic breast cancer.
    O'Shaughnessy JA; O'Regan R; Isaacs C
    Clin Adv Hematol Oncol; 2020 Sep; 18 Suppl 15(9):1-20. PubMed ID: 33843838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.
    Burstein HJ; Sun Y; Dirix LY; Jiang Z; Paridaens R; Tan AR; Awada A; Ranade A; Jiao S; Schwartz G; Abbas R; Powell C; Turnbull K; Vermette J; Zacharchuk C; Badwe R
    J Clin Oncol; 2010 Mar; 28(8):1301-7. PubMed ID: 20142587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval.
    Stoen E; Kagihara J; Shagisultanova E; Fisher CM; Nicklawsky A; Kabos P; Borges VF; Diamond JR
    Breast Cancer Res Treat; 2021 Jun; 187(3):883-891. PubMed ID: 33625615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neratinib Approved for HER2+ Breast Cancer.
    Cancer Discov; 2017 Sep; 7(9):OF1. PubMed ID: 28778899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate.
    Kotecki N; Gombos A; Awada A
    Expert Rev Anticancer Ther; 2019 Jun; 19(6):447-454. PubMed ID: 31082272
    [No Abstract]   [Full Text] [Related]  

  • 29. HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.
    Ben-Baruch NE; Bose R; Kavuri SM; Ma CX; Ellis MJ
    J Natl Compr Canc Netw; 2015 Sep; 13(9):1061-4. PubMed ID: 26358790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neratinib: First Global Approval.
    Deeks ED
    Drugs; 2017 Oct; 77(15):1695-1704. PubMed ID: 28884417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER
    Sudhan DR; Schwarz LJ; Guerrero-Zotano A; Formisano L; Nixon MJ; Croessmann S; González Ericsson PI; Sanders M; Balko JM; Avogadri-Connors F; Cutler RE; Lalani AS; Bryce R; Auerbach A; Arteaga CL
    Clin Cancer Res; 2019 Jan; 25(2):771-783. PubMed ID: 30274983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion.
    Caputo R; Buono G; Di Lauro V; Cianniello D; Von Arx C; Pensabene M; Pagliuca M; Pacilio C; Di Rella F; Verrazzo A; Martinelli C; Nuzzo F; De Laurentiis M
    Future Oncol; 2023 Aug; 19(24):1695-1708. PubMed ID: 37605877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
    Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
    Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and
    Collins DM; Conlon NT; Kannan S; Verma CS; Eli LD; Lalani AS; Crown J
    Cancers (Basel); 2019 May; 11(6):. PubMed ID: 31141894
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
    Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB
    J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.
    Freedman RA; Gelman RS; Wefel JS; Melisko ME; Hess KR; Connolly RM; Van Poznak CH; Niravath PA; Puhalla SL; Ibrahim N; Blackwell KL; Moy B; Herold C; Liu MC; Lowe A; Agar NY; Ryabin N; Farooq S; Lawler E; Rimawi MF; Krop IE; Wolff AC; Winer EP; Lin NU
    J Clin Oncol; 2016 Mar; 34(9):945-52. PubMed ID: 26834058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
    Cocco E; Javier Carmona F; Razavi P; Won HH; Cai Y; Rossi V; Chan C; Cownie J; Soong J; Toska E; Shifman SG; Sarotto I; Savas P; Wick MJ; Papadopoulos KP; Moriarty A; Cutler RE; Avogadri-Connors F; Lalani AS; Bryce RP; Chandarlapaty S; Hyman DM; Solit DB; Boni V; Loi S; Baselga J; Berger MF; Montemurro F; Scaltriti M
    Sci Signal; 2018 Oct; 11(551):. PubMed ID: 30301790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathophysiology of neratinib-induced diarrhea in male and female rats: microbial alterations a potential determinant.
    Secombe KR; Ball IA; Shirren J; Wignall AD; Keefe DM; Bowen JM
    Breast Cancer; 2021 Jan; 28(1):99-109. PubMed ID: 32683606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neratinib (HKI-272) in the treatment of breast cancer.
    López-Tarruella S; Jerez Y; Márquez-Rodas I; Martín M
    Future Oncol; 2012 Jun; 8(6):671-81. PubMed ID: 22764764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Category "viewpoints and debates" Is trastuzumab as a single agent obsolete in early breast cancer? Yes.
    Bonnefoi H; Chakiba C
    Breast; 2019 Feb; 43():146-148. PubMed ID: 30739644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.